SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ampio Pharmaceuticals, Inc.

August 8, 2018

NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces it has commenced an investigation of Ampio Pharmaceuticals, Inc. (“Ampio” or “the Company”) (NYSE American: AMPE) concerning possible violations of federal securities laws.

On August 7, 2018, Ampio filed a Form 8-K with the U.S. Securities and Exchange Commission providing an update on the U.S. Food and Drug Administration’s review of the AP-003-A and AP-003-C trials. Ampio disclosed that it had met with the FDA in July and received a response letter, notifying the Company that the AP-003-A study alone “does not appear to provide sufficient evidence of effectiveness to support” its Biologics License Application. Following this news, shares of Ampio were down more than 78% on intraday trading on August 8, 2018. To obtain additional information, go to:


or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: Levi & Korsinsky, LLPEduard Korsinsky, Esq.30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171 www.zlk.com

Update hourly